This article has been updated to correct information on the firm's tests.

NEW YORK (GenomeWeb News) – Cancer Genetics anticipates raising up to about $49 million in its initial public offering, the genomics-based test development company said in an amended Form S-1 filed last week with the US Securities and Exchange Commission.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.